Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Pisano

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
ESMO Open|January 4, 2025
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trialB Pellegrino, E D Capoluongo, M Bagnoli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancerC K Lee, R J Simes, C Brown, et al.
Cancer Research|June 8, 2026
Lactate-Activated GPR132 Signaling Drives a Tumor Microenvironmental Autocrine Metabolic Loop in Kidney CancerDazhi Wang, Timothy M Horton, Kyutae David Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2018
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancerM C Piccirillo, G Scambia, A Bologna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2024
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapyS Pignata, D Califano, D Lorusso, et al.
ESMO Open|September 26, 2022
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trialE D Capoluongo, B Pellegrino, L Arenare, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 20, 2025
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 studyR S Kristeleit, S Ghamande, A Lisyanskaya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2024
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trialB J Monk, M P Barretina-Ginesta, B Pothuri, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
ESMO Open|January 4, 2025
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trialB Pellegrino, E D Capoluongo, M Bagnoli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancerC K Lee, R J Simes, C Brown, et al.
Cancer Research|June 8, 2026
Lactate-Activated GPR132 Signaling Drives a Tumor Microenvironmental Autocrine Metabolic Loop in Kidney CancerDazhi Wang, Timothy M Horton, Kyutae David Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2018
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancerM C Piccirillo, G Scambia, A Bologna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2024
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapyS Pignata, D Califano, D Lorusso, et al.
ESMO Open|September 26, 2022
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trialE D Capoluongo, B Pellegrino, L Arenare, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 20, 2025
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 studyR S Kristeleit, S Ghamande, A Lisyanskaya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2024
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trialB J Monk, M P Barretina-Ginesta, B Pothuri, et al.
Pageof 8